Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Silibinin meglumine ameliorates hepatic encephalopathy via inhibiting UCP2-mediated oxidative stress and mitochondrial dysfunction.

Chinese journal of natural medicines·2026
Same author

Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.

Emerging microbes & infections·2026
Same author

Persistent inflammatory markers existing with HIV-1 reservoirs in antiretroviral therapy treated HIV-1 individuals.

Cytokine·2026
Same author

Synergistic Intra- and Inter-Nanozyme Electron Transfer through Interfacial Assembly for Enhanced Multi-Enzyme Activity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

ADAM8 in macrophages exacerbates sepsis-induced cardiomyopathy by impeding efferocytosis.

Frontiers in immunology·2025
Same author

Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.

Bioactive materials·2025
Same journal

Localized pH regulation via a dynamic proton-converting raft for gastroesophageal reflux disease.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Systems engineering of engineered live biotherapeutics: A discovery-to-translation framework for streamlining microbiome therapeutic development.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Tunable rigid spikes on virus-like porous silica enable mechanistically controlled nanovaccine platforms.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Metabolic regulation-driven nanoparticles for tumor vulnerabilization and enhanced photodynamic therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Engineering ROS-responsive size-transformable nanoassemblies to reprogram plaque microenvironment and activate

Yanyan Wang1, Kaishun Qi2, Youyou Li2

  • 1Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Henan University, Kaifeng 475000, People's Republic of China; Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu 210009, People's Republic of China.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|June 2, 2026
PubMed
Summary
This summary is machine-generated.

This study introduces a novel nanotherapy combining antioxidant and autophagy-enhancing properties to treat atherosclerosis. The treatment effectively reduces plaque vulnerability and improves cardiovascular event outcomes.

Keywords:
AtherosclerosisCationic antioxidant dextran derivativeMacrophage autophagy activationNanoassembliesROS-scavengingSynergistic nanotherapeutic strategy

Related Experiment Videos

Last Updated: Jun 4, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Nanomedicine

Background:

  • Oxidative stress and impaired macrophage autophagy contribute to vulnerable atherosclerotic plaques and cardiovascular events.
  • Current single-target therapies for atherosclerosis are insufficient.
  • A dual-action therapeutic strategy is needed to address both oxidative stress and autophagy dysfunction.

Purpose of the Study:

  • To develop and evaluate a novel nanotherapeutic system for synergistic atherosclerosis treatment.
  • To combine reactive oxygen species (ROS) scavenging with autophagy induction for enhanced plaque stabilization.
  • To investigate the efficacy of the nanotherapy in preclinical models of atherosclerosis.

Main Methods:

  • Development of a cationic antioxidant dextran derivative (DKT) for co-delivery of rapamycin-loaded reconstituted high-density lipoprotein (RC-rHDL).
  • Formation of ROS-triggered disassembling nanoassemblies (RT-rHDL) via electrostatic interactions.
  • In vitro assessment of foam cell formation, inflammation, and apoptosis.
  • In vivo evaluation of plaque burden, stability, and inflammation in apoE-/- mice.

Main Results:

  • RT-rHDL nanoassemblies demonstrated efficient plaque targeting and ROS-triggered disassembly.
  • In vitro studies showed inhibition of foam cell formation, inflammation, and apoptosis.
  • In vivo treatment significantly reduced plaque size, necrotic core area, and inflammation, enhancing plaque stability.
  • Therapeutic benefits were attributed to reduced oxidative stress and restored macrophage autophagy.

Conclusions:

  • Simultaneous modulation of cellular functions and the plaque microenvironment is crucial for effective atherosclerosis treatment.
  • The developed RT-rHDL nanoassemblies represent a promising synergistic nanotherapeutic strategy for atherosclerosis.
  • This approach offers a novel pathway for managing vulnerable atherosclerotic plaques and preventing cardiovascular events.